Plain-language summary

This Phase 2 trial is testing golidocitinib and GEMOX for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

golidocitinib (DRUG): 150mg qd po | GEMOX (DRUG): Gemcitabine: 1000mg/m2, d1; Oxaliplatin:100mg/m2, d1

Drugs / treatments

golidocitinib, GEMOX

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details